Document is current
Any future updates will be listed below
-
Authors
Bock, Allison M.
Nowakowski, Grzegorz S.
Wang, Yucai
- License Information
-
More Information
Article History
Accepted: 6 August 2021
First Online: 19 February 2022
Declarations
:
: Allison M. Bock declares that she has no conflict of interest. Grzegorz S. Nowakowski has received research funding (paid to his institution) from Celgene/Bristol-Myers Squibb, Roche, Genentech, and NanoString Technologies, and has received compensation for service as a consultant from MorphoSys, Celgene/Bristol-Myers Squibb, Roche, Genentech, Kite Pharma, Ryvu Therapeutics, Selvita, Curis, Karyopharm Therapeutics, Bantam Pharmaceutical, Daiichi Sankyo, Zai Lab, Incyte Corporation, TG Therapeutics, and Blueprint Medicines. Yucai Wang has received research funding (paid to his institution) from Incyte Corporation, InnoCare, LOXO Oncology, Novartis, and Genentech; and has served on advisory boards for Incyte Corporation, LOXO Oncology, Eli Lilly, and TG Therapeutics. All compensation was paid directly to his institution.
